SynCardia Systems manufactures the SynCardia Total Artificial Heart, a medical device designed to replace both failing ventricles in patients with advanced biventricular heart failure. The device is FDA-approved and intended for transplant-eligible patients at imminent risk of death, providing complete heart replacement while they await donor heart transplantation. SynCardia would be a natural referral for cardiac specialists managing patients with severe biventricular failure who need bridging therapy to transplant, and would likely refer other patients to cardiac transplant centres and heart failure specialists.